Search
DL-alpha tocopheryl acetate
go.drugbank.com/drugs/DB14477ApprovedMixtures: Panaflex Cool Patch, Cavan OneAmphetamine
go.drugbank.com/drugs/DB00182ApprovedIllicitInvestigationalAmphetamine, a compound discovered over 100 years ago, is one of the more restricted controlled drugs. … Amphetamine structure presents one chiral center and it exists in the form of dextro- and levo-isomers.[A18540] The first product of Smith, Kline and French was approved by the FDA on 1976.
Melphalan flufenamide
go.drugbank.com/drugs/DB16627ApprovedWithdrawnMelphalan flufenamide, also known as melflufen or J1, is a prodrug of melphalan. Melphalan flufenamide is more readily uptaken by cells than melphalan, and is cleaved to the active metabolite by aminopeptidases. In vitro models show that...
Gallium Ga-68 gozetotide
go.drugbank.com/drugs/DB16019ApprovedInvestigational[L26981] Prostate cancer is one of the most commonly diagnosed cancers among men in Western countries and many patients treated with androgen-deprivation therapy relapse with castration-resistant prostate
Gedatolisib
go.drugbank.com/drugs/DB11896ApprovedInvestigational, with or without [palbociclib], for adults with HR-positive, HER2-negative locally advanced or metastatic breast cancer without a PIK3CA mutation detected, following progression on or after at least one
Cefotiam
go.drugbank.com/drugs/DB00229ApprovedOne of the cephalosporins that has a broad spectrum of activity against both gram-positive and gram-negative microorganisms.
Epicriptine
go.drugbank.com/drugs/DB11275ApprovedTogether with the alpha-dihydroergocryptine, it represents one-third of the ergoloid mesylate mixture. Epicriptine differs from the alpha form on the position of one methyl group.
Relacorilant
go.drugbank.com/drugs/DB14976ApprovedInvestigationalRelacorilant is a first-in-class, selective glucocorticoid receptor antagonist. Originally investigated to manage the metabolic and endocrinologic complications of hypercortisolism, such as Cushing’s syndrome, its clinical utility has pi...
Avalglucosidase alfa
go.drugbank.com/drugs/DB16099ApprovedInvestigational[A232960] On August 6, 2021, avalglucosidase alfa-ngpt was approved by the FDA under the market name Nexviazyme to treat patients one year of age and older with late-onset Pompe disease.
Belantamab mafodotin
go.drugbank.com/drugs/DB15719ApprovedInvestigationalWithdrawn[L53673] Later that year in October of 2025, belantamab was granded full approval by the FDA for the a similar indication to the Health Canada one. [L54331]